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Abstract The aim of this study was to present how opioids
are used in an acute pain relief and palliative care unit
(APRPCU), where many patients with difficult pain condi-
tions are admitted from GPs, home palliative care programs,
oncology departments, other hospitals or emergency units,
and other regional places. From a consecutive sample of
cancer patients admitted to an APRPCU for a period of
6 months, patients who had been administered opioids were
included in this survey. Basic information was collected as
well as opioid therapy prescribed at admission and, subse-
quently, during admission and at time of discharge. Patients
were discharged once stabilization of pain and symptoms
were obtained and the treatment was considered to be opti-
mized. One week after being discharged, patients or rela-
tives were contacted by phone to gather information about
the availability of opioids at dosages prescribed at time of
discharge. One hundred eighty six of 231 patients were
specifically admitted for uncontrolled pain, with a mean
pain intensity of 6.8 (SD 2.5). The mean dose of oral
morphine equivalents in patients receiving opioids before
admission was 45 mg/day (range 10–500 mg). One hundred
seventy five patients (75.7 %) were prescribed around the
clock opioids at admission. About one third of patients
changed treatment (opioid or route). Forty two of 175
(24 %), 27/58 (46.5 %), 10/22 (45.4 %), and 2/4 (50 %)
patients were receiving more than 200 mg of oral morphine
equivalents, as maximum dose of the first, second, third, and
fourth opioid prescriptions, respectively. The pattern of
opioids changed, with the highest doses administered with
subsequent line options. The mean final dose of opioids,
expressed as oral morphine equivalents, for all patients was
318 mg/day (SD 798), that is more than six times the doses
of pre-admission opioid doses. One hundred eighty six
patients (80.5 %) were prescribed a breakthrough cancer
pain (BTcP) medication at admission. Sixty five patients
changed their BTcP prescription, and further 27 patients
changed again. Finally, eight patients were prescribed a
fourth BTcP medication. Of 46 patients available for inter-
view, the majority of them (n=39, 84 %) did not have
problems with their GPs, who facilitated prescription and
availability of opioids at the dosages prescribed at dis-
charge. For patients with severe distress, APRPCUs may
guarantee a high-level support to optimize pain and symp-
tom intensities providing intensive approach and resolving
highly distressing situations in a short time by optimizing
the use of opioids.
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Introduction
Pain is one of the most prevalent, burdensome, and feared
symptoms among cancer patients. Pain is experienced by at
least 30 % of patients undergoing an oncological treatment
for metastatic disease and by more than 70 % of advanced
cancer patients. WHO guideline application has reported to
achieve satisfactory pain relief in up to 90 % of patients with
cancer pain, by using simple measures, even at home [1].
However, even when the basic principles for the use of
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analgesic drugs are adhered to, some patients experience
insufficient pain relief, possibly because of the underuse of
opioids. Mean doses of opioids vary widely between set-
tings due to different population examined, generally at
home, oncologic ward, hospice, or outpatient clinic. In a
cross-sectional survey of 3,030 cancer patients among 143
palliative care centers in 21 European countries, only a mi-
nority of the patients who used opioids were receiving high
doses [2]. Of those patients receiving morphine, approximate-
ly three quarters were treated with doses less than 150 mg/day.
This observation may reflect that most patients are adequately
treated at low or moderate doses of opioids or, more likely,
that the doses are not appropriately increased in those patients
who need the opioid treatment in the high-end dose range.
Indeed, when higher doses of opioids are appropriately used
for controlling pain, they have been found to be safe and
effective when used by skilled people [3–5].
In a more recent large epidemiological study, patients who
were already treated were considered poorly treated, accord-
ing to a “generous” score such as the pain management index,
which considers well treated all the patients on strong opioids,
independently of the dose underestimating even poorer pain
control [6]. Thus, even in specialized centers, opioid doses are
underused or not optimally prescribed.
The acute pain relief and palliative care units (APRPCUs)
have been differently described in the literature. These centers
are characterized by the admission of a very selected cancer
population presenting for pain and symptom management of
severe intensity during all the trajectory of disease, also in
patients who are still receiving active treatment of disease and
not only at the end of life [7–10].
Another important question is what happens when
patients optimally treated are discharged home. Despite
achieving an adequate pain relief, patients discharged from
hospital may have problems in obtaining the opioids pre-
scribed because of GPs’ concerns regarding the doses, as
observed some years ago in a previous survey [11].
The aim of this study was to present how opioids are used
in an APRPCU, where many patients with difficult pain
conditions are admitted from GPs, home palliative care
programs, oncology departments, other hospitals or emer-
gency units, and other regional places. The secondary ob-
jective was to evaluate the effectiveness of this prescription
when patients are discharged from the unit.
Patients and methods
The protocol study was approved by the ethical committee of
the University of Palermo, and informed consent to use the
data was obtained from patients or relatives. From a consec-
utive sample of cancer patients admitted to an APRPCU for a
period of 6 months, patients who had been administered with
opioids were included in this survey. Basic information was
recorded, including tumor diagnosis, age, and gender. The
activity of the APRPCU has been described elsewhere [9].
Other than providing medical treatment of pain and symp-
toms, time is spent for communication, education, and psy-
chological care, particularly focusing on the individual needs.
Special attention is paid to continuous education and practical
training of the nurses during the rounds and in appropriate
meetings in which the emerging cases are discussed. Patients
are discharged at home once the most stable condition possi-
ble is reached, unless symptom control cannot be guaranteed
for different reasons, including unfavorable clinical condi-
tions, relatives unable to face the terminal phase at home,
unavailability of home care, and so on.
Opioid therapy, including type of opioids, the maximum
dose achieved with each opioid, and route of administration,
prescribed at admission and, subsequently, during admission
and at time of discharge was recorded. According to local
policy, opioids were administered with the aim of achieving
adequate pain relief (with an intensity of 4 or less on a
numerical scale from 0 to 10), a limited number of break-
through pain episodes (three episodes per day or less), and
acceptable level of adverse effects (intensity of less than 2,
in a scale from 0 to 3). Opioids, doses, and routes were used
according to the clinical need to obtain the maximum ben-
efit, individualizing the treatment. Opioid/route switching
was performed by using initial conversion ratios previously
described [12]. Patients were discharged once stabilization
of pain and symptoms were obtained and the treatment was
considered to be optimized.
Opioid escalation index (OEI), in milligrams or as percent-
age, was calculated from data recorded at admission and at
discharge, according to the following formula: OEI % :
x yð Þ=y½ =days 100, where x is the last dose before death
and y is the dose at −7, both expressed as equivalents of oral
morphine; and OEImg is (x–y)/days [13]. For each prescrip-
tion, the maximum dose of each opioid was recorded, as oral
morphine equivalents. Oral morphine equivalents were calcu-
lated according to department policy [12], the conversion
ratios used among opioids and routes of administration being
the following: oral morphine 100=intravenous morphine 33=
TTS buprenorphine 1.3=TTS Fentanyl 1=Intravenous fen-
tanyl 1=oral methadone 20=intravenous methadone 16=oral
oxycodone 70, transdermal buprenorphine 1.3.
One week after being discharged, patients or relatives
were contacted by phone to gather information about the
availability of opioids at dosages prescribed at time of
discharge, particularly regarding the collaboration of GPs.
Statistical analysis
Data were collected and analyzed by the SPSS Software
14.0 version (SPSS, Inc.,Chicago, Ill, USA). Statistical
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analysis of quantitative data, including descriptive statistics,
was performed for all the items. Frequency analysis was
performed with chi-square test. The paired-sample Student’s
t test was used to compare the differences in opioid doses at
the time intervals. The one-way analysis of variance was
used to compare the different parametric variables. All P
values were two-sided, and P values less than 0.05 were
considered to indicate statistical significance.
Results
Two hundred thirty one patients were admitted to the
APRPCU in the period taken into consideration. The mean
age was 62.3 years (SD 11.8), and 117 patients were males.
Almost all patients had an ECOG value of 2–3. The primary
diagnoses were in a rank order: urogenital (n=45), lung
(n=39), gastrointestinal (n=32), breast (n=30), pancreas
(n=21), head–neck (n=18), liver (n=13), and others (n=33).
The median time of admission was 7 days (range 3–15).
One hundred eighty six patients were specifically admitted
for uncontrolled pain. Their mean pain intensity was 6.8 (SD
2.5), and they were receiving different regimens of analgesics,
including non-opioid and opioid drugs, unsuccessfully. The
mean dose of oral morphine equivalents in patients receiving
opioids before admission was 45 mg/day (range 10–500 mg).
One hundred seventy five patients (75.7 %) were pre-
scribed around the clock (ATC) opioids at admission. The
maximum doses achieved of the first analgesic drugs
achieved after dose titration are described in Table 1. Of
these, ten patients were prescribed a combination of opioids
or routes of administration, and seven of them were pre-
scribed very high doses of opioids, as expressed in oral
morphine equivalents. Three of them were treated with
a combination of intrathecal opioids and local anes-
thetics, associated with systemic opioids (two patients
on hydromorphone and one patient on oral morphine).
Doses of intrathecal morphine achieved were relatively
high (60 mg/day), and the global oral morphine equiv-
alents were more than 6,000 mg/day.
The number of patients who changed treatment (opioid or
route) and the maximum dose of each line of treatment,
expressed as oral morphine equivalents, are presented in
Table 1. Fifty eight, 22, and 4 patients were prescribed a second,
a third, and a fourth opioid/route, respectively. The OEI% and
OEImg were 3.9 (SD=13) and 2.1 (SD=19), respectively.
Forty two of 175 (24 %), 27/58 (46.5 %), 10/22 (45.4 %),
and 2/4 (50 %) patients were receiving more than 200 mg of
Table 1 Number of patients who were prescribed opioids and route of opioid administration
1° opioid 2° opioid 3° opioid 4° opioid Discharge
Number Dose mg/day Number Dose mg/day Number Dose mg/day Number Dose mg/day Number Dose mg/day
MO os 24 94 (111) 12 184 (108) 1 180 15 165 (150)
MO par (Iv-sc) 15 158 (100) 6 580 (511) 4 781 (890) 1 90 8 960 (1344)
ME os 11 377 (364) 8 662 (672) 6 226 (119) 1 225 23 441 (486)
ME iv 7 1,025 (1238) 6 230 (76) 1 375 1 125 3 185 (63)
HY os 26 360 (432) 10 443 (423) 7 333 (338) 1 240 37 618 (1358)
OX–paracetamol 5 26 (4) 2 38 (11)
OX os 16 48 (30) 2 60 (42) 12 96 (59)
OX–N os 16 48 (30) 1 20 12 44 (31)
CO–paracetamol 2 37 (10) 2 38 (11)
FEN TD 34 182 (194) 10 135 (106) 2 75 (63) 37 244 (644)
BUP TD 8 43 (25) 2 35 (7) 1 60 9 36 (16)
Tramadol 4 30 (0) 3 30 (0)
TAP 10 57 (38) 1 90 9 57 (41)
2 opioids or routes 10 9
Total (mean) 175 205 (385) 58 318 (395) 22 467 (851) 4 170 (74) 175 318 (798)
Columns: 1° opioid=number of patients and maximum dose (SD) of the first opioid prescribed at admission; 2°opioid=number of patients who
required a second opioid and maximum mean doses prescribed (SD); 3° opioid=number of patients who required a third opioid and maximum
mean doses prescribed(SD); 4° opioid=number of patients required a fourth opioid and maximum mean doses prescribed (SD); Discharge=number
of patients and final opioid prescribed at discharge, and mean doses
Drugs:MO os oral morphine,MO par parenteral morphine,ME os oral methadone,ME iv intravenous methadone, HYos oral hydromorphone, OX–
paracetamol oxycodone and paracetamol (it is reported the dose of oxycodone), OX os slow-release oxycodone, OX–N os oxycodone–naloxone
combination (it is reported the dose of oxycodone), CO–paracetamol codeine and paracetamol (it is reported the dose of codeine), FEN TD
transdermal fentanyl, BUP TD transdermal buprenorphine, TAP tapentadol, 2 opioids or route=opioid combination (doses are not reported). Total
doses are expressed as oral morphine equivalents
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oral morphine equivalents, as maximum dose of the first,
second, third and forth opioid prescriptions, respectively.
The pattern of opioids changed, with the highest doses
administered with subsequent line options, especially for
parenteral morphine, oral methadone, and hydromorphone.
The mean final dose of opioids, expressed as oral morphine
equivalents, for all patients was 318 mg/day (SD 798).
Older patients (>65 years) received lower doses of oral
morphine equivalents (p=0.004) in comparison with adults
at the first opioid prescription, but no difference were found
in the subsequent lines. No gender differences were found.
The mean pain intensity at time of discharge was 3 (SD 0.9).
One hundred eighty six patients (80.5 %) were prescribed a
breakthrough cancer pain (BTcP)medication at admission. This
means that some patients were initially prescribed an as needed
medicationwithout ATCmedication, possibly due to an attempt
of detoxification of patients presenting with opioid-induced
toxicity. The number of patients who were prescribed BTcP
medication and their doses in the first instance and then
changed prescription is presented in Table 2. The majority of
patients received parenteral opioids such as morphine and
methadone, and transmucosal fentanyl with different delivery
systems. Twenty six patients were prescribed non-opioids or
opioids for moderate pain. Sixty five patients changed their
BTcP prescription, and further 27 patients changed again. Fi-
nally, eight patients were prescribed a fourth BTcP medication.
Five patients died in the APRPCU during the admission.
Three patients were discharged to other hospitals: two
patients were transferred to hospice and one patient was
transferred to an orthopedic ward. Data regarding emerging
problems with prescription after discharge were available in
46 patients only.
Only 39 % of patients were available for interview. The
majority of them (n=39, 84 %) did not have problems with
their GPs, who facilitated prescription and availability of
opioids at the dosages prescribed at discharge. Six patients
encountered some problems with opioid prescription, and in
one of these cases, it was due to the high doses of opioids
prescribed at discharge.
Discussion
The findings of this study show that many patients may
require complex treatments to obtain an adequate pain relief.
As expected, most patients were admitted for pain control,
Table 2 Prescription of BTcP medication
1° BTcP med 2° BTcP med 3° BTcP med 4° BTcP med Discharge
Number Mean dose
(SD)
Number Mean dose
(SD)
Number Mean dose
(SD)
Number Mean dose
(SD)
Number Mean dose
(SD)
MO os mg 16 16 (49) 4 9 (5) 1 30 1 25 21 11 (19)
MO par (Iv-sc) mg 53 17 (30) 11 41 (68) 4 10 (6) 2 11(12) 31 33 (54)
ME os mg 1 5 1 5 1 5
ME iv mg 10 23 (19) 8 12 (15) 1 13 3 13(11) 4 19 (21)
SLF (μg) 18 394 (176) 11 304 (131) 5 680 (521) 1 600 23 365 (210)
FBT (μg) 26 622 (724) 15 626 (57) 9 911 (1,300) 44 613 (756)
OTFC (μg) 6 667 (854) 1 1,600 1 600 6 867 (918)
INFS (μg) 10 180 (129) 8 156 (111) 1 200 1 200 13 158 (91)
PCFE (μg) 9 255 (2,067) 3 300 (173) 3 300 (173) 9 233 (100)
Tramadol (mg) 11 39 (16) 11 39 (16)
OX–paracetamol 16 6 (2) 1 10 11 5 (1)
CO–paracetamol 5 376 (247) 5 376 (247)
Ketorolac 2 20 (14) 1 20 2 15 (21)
Paracetamol 3 550 (636) 3 550 (636)
INFS-PCFE 3 300–500 (173) 2 450 (212)
Total 186 65 27 8 186
Columns: 1° BTcP med=number of patients and maximum dose (SD) of the first BTcP medication prescribed at admission; 2° BTcP med=number
of patients who required a second BTcP medication and maximum mean doses prescribed(SD); 3° BTcP med=number of patients who required a
third BTcP medication and maximum mean doses prescribed(SD); 4° BTcP med=number of patients who required a fourth BTcP medication
maximum mean doses prescribed (SD); Discharge=number of patients and final BTcP medication prescribed at discharge, and mean doses
Drugs: MO os oral morphine, MO par parenteral morphine, ME os oral methadone, ME iv intravenous methadone, SLF sublingual fentanyl, FBT
fentanyl buccal tablet, OTFC oral transmucosal fentanyl citrate, INFS intranasal fentanyl, PCFE pectin nasal fentanyl, OX–paracetamol oxy-
codone–paracetamol (it is reported the dose of oxycodone), CO–paracetamol codeine–paracetamol (it is reported the dose of codeine)
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were undertreated, and were receiving inadequate analgesic
treatment. This explains the large number of patients requir-
ing intravenous morphine for a rapid titration, commonly
used for patients who present with severe pain. More than
20 % patients received more than 200 mg/day of oral mor-
phine equivalents, and three patients underwent an intrathe-
cal therapy, with very high doses of spinal morphine and
other systemic opioids. These opioid dosages were quite
higher in respect to home care, oncological wards or hospice
care patients recruited in largest studies [2, 6, 14], revealing
a major complexity of pain syndromes. Doses of oral mor-
phine equivalents at discharge were 8–10 times than the
doses administered before admission. This is confirmed by
the need to change opioids and/or routes in a consistent
number of patients. One third of patients changed treatment
and a minority of patients was administered a fourth line of
treatment. Of interest, despite the opioid/route switching,
which potentially should be translated in a decrease of
equivalent oral morphine doses as often it occurs, opioid
doses were increased in time at the second and the third
switches.
According to local policy, patients were discharged only
when the balance between analgesia and adverse effects was
optimized [9]. This means that the final treatment was
considered to be effective, when stabilization of symptoms
is achieved. Of interest, the direction of patients after dis-
charge was different, including home care assistance, oncol-
ogy ward for a further evaluation to continue anticancer
treatments, and only in a few cases hospice care in patients
with an expected short survival, while a minimal amount of
patients died in the unit, confirming previous data on the
characteristics of patients admitted to the APRPCU [9]. It
cannot be excluded that patients may further increase opioid
dosage in the course of disease trajectory, as most patients
were discharged with a relative long-survival expectancy.
Most of patients who received an opioid treatment were
prescribed a BTcP medication, particularly at admission,
when opioids doses were increased while providing an extra
analgesia during titration. In fact, the first prescription was
prevalently intravenous morphine, which is the favorite drug
until stabilization is obtained. Prescription of BTcP medica-
tion changed, not necessarily because poor efficacy but to
provide a rapid as easier delivery system for patients pre-
pared to be discharged, according to the clinical need and
patients’ convenience. In most cases, the different formula-
tions of transmucosal fentanyl and parenteral morphine were
preferred, according to the temporal pattern of most epi-
sodes of BTcP. The pattern of BTcP medications was pro-
foundly different from those recorded in hospice or
oncological settings, where new products providing rapid
analgesia were seldom prescribed [15–18]. Finally, doses
prescribed were relatively high, like the doses of around the
clock opioids, due to the local policy of administering doses
proportional to opioid basal regimen [19]. This approach has
been found as effective as safe for patients [20–22].
Despite the low number of patients available for a phone
contact, data recorded were encouraging, as most patients
could continue the treatment despite the large amount of
opioids prescribed as around the clock and as a BTcP
medication. In comparison to a previous survey, GPs were
more compliant and less reluctant to prescribe opioids sug-
gested at discharge, possibly because of the trust on the
institution of provenience.
The appropriate use of opioids and continuous care seem
to be worldwide determinant to achieve adequate pain con-
trol in most patients. The appropriate use of opioids may
provide appreciable results, with more than 90 % of patients
with mild pain for prolonged periods of time, even at home
in an unselected population of cancer patients [23]. Howev-
er, most patients continue to be undertreated by opioids,
particularly in Italy [24]. In a home palliative setting, pain
was fairly well controlled in the final week of life, with 20 %
experiencing severe continuous pain [25]. Pain control in
patients hospitalized in oncology centers was unsatisfactory
and prescription inadequate in about 50 % of patients [26].
In another study, 82 % of patients had received inadequate
treatment of cancer pain [27]. In a survey performed in a
large number of Italian oncologic centers, despite receiving
strong opioids, about 85 % of patients had their pain uncon-
trolled [28]. The recourse to strong opioids seems to be
inadequate or delayed in a substantial percentage of patients,
even when recruiting patients from the most traditional
hospital with the longest history of assessment and treatment
of cancer pain [29]. In a district of northern Italy, it has been
estimated that only 38 % of opioid prescriptions were ade-
quate and the opioid prescription inadequacy increased with
the length of time from first prescription to patient death
[30]. In a multicenter survey performed in a large number of
palliative care units, hospice and home care, as well as
oncological units, results suggest that the recourse to
WHO third-level drugs still seems to be delayed in a sub-
stantial percentage of patients. This delay is probably related
to several factors affecting practice in participating centers
and suggests that the quality of cancer pain management in
Italy deserves specific attention and interventions aimed at
improving patients’ outcomes [6]. In Italy, the use of opioids
in the management of cancer pain has been for years at the
lowest levels compared with other European countries, and
this could potentially amplify the figures regarding the
undertreatment of cancer pain observed all over the world
[2, 24, 31]. Indeed, similar findings have been reported in
most developed countries [32, 33].
It seems clear that it is necessary to resolve the most
difficult cases in settings which can provide optimal anal-
gesia because of a high-level experience and confidence
with opioid treatment. The role of APRPC team is to assess
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and manage patients’ and families’ care needs during the
course of the entire disease. There are several time-
consuming tasks that make it increasingly difficult for a
busy oncologist to address multiple palliative care needs
for the pharmacological treatment of symptoms, education
and counseling, and family support [7, 8]. This approach
may be cost-effective and allows patients to be stabilized,
even on higher doses of opioids, and then to be discharged to
other settings to continue the treatment while providing advi-
ces and education [34]. Data from literature suggests that it is
likely that such kind of patients may not be optimally treated
in other potentially specialistic settings [6]. For example,
patients with complex clinical situations, who were success-
fully switched in an APRPCU could maintain their symptom
control successfully when discharged home, with only a mi-
nority of them loosing the clinical benefit for different reasons
[35]. Several reports have described the components of inno-
vative palliative care programs that include APRPCUs and the
demographic and symptom profiles of patients admitted to
such units, as well as cost-sparing end efficiency [36–42]. In
contrast to traditional inpatient hospice, these units operate
exactly like any other acute inpatient unit and are subjects to
the same standard of clinical competence, administrative reg-
ulation, and financial responsibility. The focus of APRPCU is
rapid symptom control with the length of stay shorter and the
death rate lower than traditional hospices. The impact of early
palliative care access is of paramount importance. Unfortu-
nately, only a small proportion of comprehensive cancer cen-
ters have inpatient palliative care units [8]. The American
Society of Clinical Oncology has steadily increased the visi-
bility of palliative care and has developed education tools to
improve oncologist skills in palliative care in the effort to
integrate both processes simultaneously, rather than in differ-
ent times and confining palliative care at the end of life [7].
Thus, APRPCUs should be developed as formal structures
within each oncological department to provide a standardized
and integrated approach.
This was an observational study, and data were not com-
pared with those gathered from other settings. Such com-
parison studies are difficult to perform because “per
definition” the type of population admitted in an acute unit,
the modality of admission, resources, and experience are
completely different and represent an obvious bias for stud-
ies of such a type. Pain and symptom intensities were not
collected as it was not the focus of the study. Indirectly,
however, it is possible to consider that pain and symptom
control was optimal, because for local policy, patients are
discharged only after an adequate symptom stabilization.
Finally, although it was not the focus of the present work,
there are other relevant activities, including psychological,
spiritual, communication issues, typical of any palliative
care setting, which are of paramount importance to allow
the best outcome of pain and symptom management.
In conclusion, for patients with severe distress, early
referral to a palliative care team during the course of disease
rather than at the end of life has been recommended [34, 43].
APRPCUs may guarantee a high-level support to optimize
pain and symptom intensities providing intensive approach
and resolving highly distressing situations in a short time by
optimizing the use of opioids.
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